Role of Sotagliflozin in Managing Heart Failure in Diabetes`

Abstract

A persistent illness called heart failure lowers heart function. Patients with chronic illnesses like diabetes and hypertension are especially vulnerable to the damage caused by this failure, which can put strain on other organs. Heart failure is more common in those with diabetes. An oral antidiabetic medication is called sotagliflozin. A dual sodium drug used to treat heart failure, sotagliflozin shows great promise. An important new family of drugs being developed to treat diabetes is the sodium-dependent glucose transporter 2 (SGLT2) inhibitors. The goal of high selectivity for the SGLT2 protein in comparison to the SGLT1 protein has guided the development of SGLT2 inhibitors. Treating diabetes through complementary insulin-independent pathways could be made possible by combining SGLT1 and SGLT2 inhibition in a single drug. Consequently, a dual SGLT1 and SGLT2 inhibitor called sotagliflozin (LX4211) has been developed. A significant reduction in postprandial glucose, an increase in glucagon-like peptide 1, and a moderate excretion of glucose in the urine are the distinguishing clinical aspects of dual inhibitors of SGLT1 and SGLT2. The usage of sotagliflozin in the treatment of diabetes may be affected clinically by these characteristics.